3’-甲氧基联苯-3-羧酸 | 168618-45-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3’-甲氧基联苯-3-羧酸
• 中文别名: 3'-甲氧基联苯-3-羧酸；3-甲氧基-联苯-3-羧酸
• 英文名称: 3'-methoxy-(1,1'-biphenyl)-3-carboxylic acid
• 英文别名: 3'-methoxy-3-biphenylcarboxylic acid；3'-Methoxybiphenyl-3-carboxylic acid；3-(3-methoxyphenyl)benzoic acid
• CAS: 168618-45-9
• 化学式: C₁₄H₁₂O₃
• mdl: MFCD03424598
• 分子量: 228.247
• InChiKey: JFPVSZXZHHOWMI-UHFFFAOYSA-N

物化性质

• 沸点：
  417.3±28.0 °C(Predicted)
• 密度：
  1.193±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P301+P312,P302+P352,P304+P340,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3’-Methoxybiphenyl-3-carboxylic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
3’-Methoxybiphenyl-3-carboxylic acid
Ingredient name:
CAS number: 168618-45-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C14H12O3
Molecular weight: 228.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3’-甲氧基联苯-3-羧酸 在 三乙基硅烷 、 palladium diacetate 、 三甲基乙酸酐 、 1,4-双(二苯基膦)丁烷 作用下， 以 甲苯 为溶剂， 反应 15.0h， 以95%的产率得到3-甲氧基联苯
  参考文献：
  名称：

  通过钯催化将羧酸高选择性降压还原为芳烃†

  摘要：

  芳基羧酸是化学合成中最丰富的底物之一，是无痕导向基团的完美例子，它是药物、天然产物和聚合物制备过程中许多过程的核心。在此，我们描述了一种通过明确定义的 Pd(0)/( II) 催化循环。该方法显示出非常广泛的底物范围，能够通过氧化还原中性机制将经典的酰基还原导向选择性脱羰。该反应的实用性在药物和天然产物的直接去功能化中得到了强调，并在与原脱羧正交的温和、氧化还原中性条件下使用可去除羧酸的一系列无痕过程中得到了进一步强调。进行了广泛的 DFT 计算以证明可逆氧化加成的优选选择性，并表明通用的氢原子转移 (HAT) 途径是可操作的。

  DOI：

  10.1039/c9sc00892f
• 作为产物：
  描述：

  3-碘苯甲酸甲酯 在 2-双环己基膦-2',6'-二甲氧基联苯 、 potassium phosphate 、 tris-(dibenzylideneacetone)dipalladium(0) 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 甲苯 为溶剂， 反应 27.0h， 生成 3’-甲氧基联苯-3-羧酸
  参考文献：
  名称：

  C-O/C-H偶联双金属协同催化羧酸脱羰杂芳基化

  摘要：

  协同双金属催化是现代合成化学的基本方法。我们报告了通过酰基 C-O/C-H 偶联对普遍存在的羧酸进行直接脱羰杂芳基化的双金属协同催化。这种新型催化体系利用铜催化剂和钯催化剂在脱羰基化中的协同作用，在没有预官能化或导向基团的情况下，通过羧酸与杂芳烃的偶联，能够高度化学选择性地合成重要的杂二芳基基序。这种协同脱羰方法使用常见的羧酸，并显示出非常广泛的底物范围（> 70 个示例），包括药物的后期修饰和生物活性剂的简化合成。进行了广泛的机理和计算研究，以深入了解反应的机理。关键步骤涉及通过铜-芳基物质与氧化加成/脱羰产生的钯（II）中间体的金属转移来交叉两个催化循环。

  DOI：

  10.1002/anie.202100949

文献信息

• Inhibitors of cathepsin S
  申请人：IRM LLC

  公开号：US20040198780A1

  公开（公告）日：2004-10-07

  The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., cathespin K). The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.

  本发明提供了用于选择性抑制蛋白酶S的化合物、组合物和方法。在一个优选方面，当至少存在另一种蛋白酶同工酶（例如，蛋白酶K）时，选择性地抑制蛋白酶S。本发明还提供了通过选择性抑制蛋白酶S来治疗受试者疾病状态的方法。
• Design and synthesis of N-(3-sulfamoylphenyl)amides as Trypanosoma brucei leucyl-tRNA synthetase inhibitors
  作者：Zezhong Li、Weixiang Xin、Qing Wang、Mingyan Zhu、Huchen Zhou

  DOI：10.1016/j.ejmech.2021.113319

  日期：2021.5

  needed. Leucyl-tRNA synthetase (LeuRS) is an attractive target for the development of antimicrobial agents. In this work, starting from the hit compound thiourea ZCL539, we designed and synthesized a series of amides as effective T. brucei LeuRS (TbLeuRS) synthetic site inhibitors. The most potent compounds 74 and 91 showed IC50 of 0.24 and 0.25 μM, which were about 700-fold more potent than the starting

  原生动物寄生虫布氏锥虫（T. brucei）引起人类非洲锥虫病（HAT），这是热带地区的一种致命且被忽视的疾病，因此迫切需要新的治疗方法。亮氨酰tRNA合成酶（LeuRS）是开发抗微生物剂的有吸引力的靶标。在这项工作中，我们从受到打击的化合物硫脲ZCL539开始，设计并合成了一系列酰胺，作为有效的布氏布鲁氏菌LeuRS（Tb LeuRS）合成位点抑制剂。最有效的化合物74和91的IC 500.24和0.25μM，比起始命中化合物的效力高700倍。还讨论了结构-活性关系。这些化合物提供了新的脚手架和先导化合物，用于抗锥虫病药物的进一步开发。
• A focused fragment library targeting the antibiotic resistance enzyme - Oxacillinase-48: Synthesis, structural evaluation and inhibitor design
  作者：Sundus Akhter、Bjarte Aarmo Lund、Aya Ismael、Manuel Langer、Johan Isaksson、Tony Christopeit、Hanna-Kirsti S. Leiros、Annette Bayer

  DOI：10.1016/j.ejmech.2017.12.085

  日期：2018.2

  β-lactamase inhibitors and today several β-lactamase inhibitors e.g. avibactam, are approved in the clinic. Our focus is the oxacillinase-48 (OXA-48), an enzyme reported to spread rapidly across the world and commonly identified in Escherichia coli and Klebsiella pneumoniae. To guide inhibitor design, we used diversely substituted 3-aryl and 3-heteroaryl benzoic acids to probe the active site of OXA-48

  当在医学界中治疗细菌感染时，β-内酰胺抗生素至关重要。然而，目前它们的效用受到β-内酰胺抗性的出现和扩散的威胁。对β-内酰胺抗生素最普遍的耐药机制是β-内酰胺酶的表达。克服由β-内酰胺酶引起的抗性的一种方法是开发β-内酰胺酶抑制剂，如今临床上已经批准了几种β-内酰胺酶抑制剂，例如阿维巴坦。我们的研究重点是oxacillinase-48（OXA-48），据报道该酶在世界范围内迅速传播，通常在大肠杆菌和肺炎克雷伯菌中得到鉴定。为了指导抑制剂的设计，我们使用了不同取代的3-芳基和3-杂芳基苯甲酸来探测OXA-48的活性位点，以进行有用的酶-抑制剂相互作用。在本研究中，合成了包含49个3-取代的苯甲酸衍生物的聚焦片段文库，并对其进行了生化表征。基于从33片段的酶复合物晶体学数据，片段可以被归类为R 1或R 2个可以通过总体结合构象相对于粘合剂到R的结合1和R 2亚胺培南的侧基。此外，发现了对未来抑
• NOVEL COMPOUNDS
  申请人：HEIMANN Annekatrin

  公开号：US20130158042A1

  公开（公告）日：2013-06-20

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R 1 , R 2 , R 3 , R 4 , Q have meanings given in the description.

  这项发明涉及公式I的化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍，如精神分裂症或认知功能下降，如痴呆症或认知障碍的药剂的方法。R1，R2，R3，R4，Q在描述中给出了含义。
• 4,5-diaryloxazole derivatives
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06025375A1

  公开（公告）日：2000-02-15

  Heterocyclic compounds of the formula: ##STR1## whereinR.sup.1 is carboxy or protected carboxy, R.sup.2 is aryl which may have suitable substituent(s), R.sup.3 is aryl which may have suitable substituent(s), A.sup.1 is lower alkylene, A.sup.2 is bond or lower alkylene and -Q- is ##STR2## etc., and pharmaceutically acceptable salts thereof which are useful as a medicament.

  式为：##STR1##其中R.sup.1是羧基或保护羧基，R.sup.2是芳基，可能有适当的取代基，R.sup.3是芳基，可能有适当的取代基，A.sup.1是较低的烷基，A.sup.2是键或较低的烷基，-Q-是##STR2##等，以及其药学上可接受的盐，可用作药物。